Dongwen Lv

Assistant Professor

UT Health San Antonio

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dongwen Lv is an Assistant Professor at UT Health San Antonio, USA. His research focuses on targeted protein degradation, particularly in relation to BCL-2 and BCL-xL proteins. Recent articles authored by him explore developments in dual degraders and peptide nanofibrils, as well as innovative approaches to enhance anti-leukemic activity and overcome toxicity issues associated with existing treatments.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

UNITED STATES

View details

Shaun Olsen

Associate Professor

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dongwen Lv

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation

Piperlongumine conjugates induce targeted protein degradation

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.

Discovery of a Novel BCL-X<sub>L</sub>PROTAC Degrader with Enhanced BCL-2 Inhibition

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity

Assays and technologies for developing proteolysis targeting chimera degraders

DT2216 - A Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Discovery of IAP-recruiting BCL-X<sub>L</sub> PROTACs as potent degraders across multiple cancer cell lines

Protein inhibitor of activated STAT1 (PIAS1) inhibits IRF8 activation of Epstein-Barr virus lytic gene expression

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Collaborators (7)

QI ZHANG

Xingui Liu

Khan Sajid

Adam Palmer

Zongtao Lin

Dongwen Lv

Shaun Olsen

Make your next move.